Xtent hanging on

After announcing plans May 15 to liquidate the company, followed by positive clinical trial results on Xtent‘s Custom NX(R) DES coronary stent that sent the company’s share price dramatically up, Xtent now has two investors potentially interested in either making a strategic inestment in, or acquiring, the company. Xtent had planned a July 9 shareholder’s meeting to address the lingering question on the company’s survival, but has postponed the meeting until August to allow the prospective investors to mull over the opportunity a bit further.


See the MedMarket Diligence Report #C245, "Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents Market, 2008-2017."

Posted via email from medmarket’s posterous

Leave a Reply